Companies /Healthcare
Charles River Laboratories International Inc
NYSE: CRL Diagnostics & Research
$299.02
▼ $2.84 (−0.94%) today
Markets closed · 2:36am ET

Charles River Laboratories (CRL) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
100%
EPS beat rate
+9.96%
Avg. EPS surprise
Consecutive EPS beats
CRL vs Market · 30-day return after each reportCRLS&P 500
−5%0%+5%+10%+7.7%+6.9%Q1 25+7.8%+2.5%Q2 25+11.6%+0.9%Q3 25−2.8%−5.5%Q4 25+4.5%+0.8%Q1 26+10.7%+0.1%Q2 26
−5%0%+5%+10%Q1 25Q3 25Q1 26
CRL EPS Trend · estimate vs actualEstimateActual
$0.00$0.90$1.80$2.70$2.07$2.34Q1 25$2.50$3.12Q2 25$2.34$2.43Q3 25$2.35$2.39Q4 25$1.94$2.06Q1 26$2.73$3.02Q2 26
$0.00$0.90$1.80$2.70Q1 25Q3 25Q1 26
CRL Revenue Trend · estimate vs actualEstimateActual
$0$300.0M$600.0M$900.0M$941.9M$984.2MQ1 25$985.1M$1.0BQ2 25$990.8M$1.0BQ3 25$987.0M$994.2MQ4 25$977.4M$995.8MQ1 26$977.2M$1.0BQ2 26
$0$300.0M$600.0M$900.0MQ1 25Q3 25Q1 26

How Often Does Charles River Laboratories Beat Earnings Estimates?

Charles River Laboratories beat EPS estimates in 6 of its last 6 reported quarters, and has beaten 6 quarters in a row.

CRL quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q2 2026 $3.02 est. $2.73 +10.65% $1.0B est. $977.2M +2.75%
Q1 2026 $2.06 est. $1.94 +5.99% $995.8M est. $977.4M +1.88%
Q4 2025 $2.39 est. $2.35 +1.91% $994.2M est. $987.0M +0.73%
Q3 2025 $2.43 est. $2.34 +3.86% $1.0B est. $990.8M +1.42%
Q2 2025 $3.12 est. $2.50 +24.59% $1.0B est. $985.1M +4.78%
Q1 2025 $2.34 est. $2.07 +12.78% $984.2M est. $941.9M +4.48%

Figures from SEC filings and company reports. Not investment advice.